loading
Precedente Chiudi:
$1.45
Aprire:
$1.46
Volume 24 ore:
22,849
Relative Volume:
0.05
Capitalizzazione di mercato:
$76.79M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-1.231
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
-9.54%
1M Prestazione:
+2.48%
6M Prestazione:
-14.30%
1 anno Prestazione:
-51.32%
Intervallo 1D:
Value
$1.40
$1.4654
Intervallo di 1 settimana:
Value
$1.40
$1.66
Portata 52W:
Value
$0.8505
$4.42

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name
Nome
Pds Biotechnology Corporation
Name
Telefono
800-208-3343
Name
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Name
Dipendente
24
Name
Cinguettio
@pdsbiotech
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
PDSB's Discussions on Twitter

Confronta PDSB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PDSB
Pds Biotechnology Corporation
1.4469 76.79M 0 -40.56M -35.28M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.68 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.97 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
316.75 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
558.36 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-11-01 Iniziato B. Riley Securities Buy
2021-06-28 Iniziato Cantor Fitzgerald Overweight
2020-11-10 Aggiornamento H.C. Wainwright Neutral → Buy
2020-05-27 Iniziato Alliance Global Partners Buy
2020-03-09 Iniziato Noble Capital Markets Outperform
2019-10-24 Iniziato Chardan Capital Markets Buy
Mostra tutto

Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie

pulisher
Jun 18, 2025

PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

Jun 18, 2025
pulisher
Jun 17, 2025

Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener

Jun 17, 2025
pulisher
Jun 14, 2025

PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 14, 2025

HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

PDS Biotech expands equity incentive plan - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK

Jun 11, 2025
pulisher
Jun 09, 2025

PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Invests $58,000 in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 09, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl

Jun 02, 2025
pulisher
Jun 02, 2025

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan

Jun 02, 2025
pulisher
May 28, 2025

PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN

May 28, 2025
pulisher
May 28, 2025

PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus

May 28, 2025
pulisher
May 27, 2025

PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus

May 27, 2025
pulisher
May 27, 2025

PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Shares - GuruFocus

May 27, 2025
pulisher
May 27, 2025

PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus

May 27, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World

May 24, 2025
pulisher
May 23, 2025

PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World

May 23, 2025
pulisher
May 23, 2025

PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq

May 22, 2025
pulisher
May 22, 2025

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - TradingView

May 22, 2025
pulisher
May 22, 2025

PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 21, 2025

PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com

May 21, 2025
pulisher
May 20, 2025

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times

May 20, 2025
pulisher
May 17, 2025

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN

May 17, 2025
pulisher
May 16, 2025

PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN

May 16, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

May 15, 2025
pulisher
May 15, 2025

PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025
pulisher
May 14, 2025

PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News

May 14, 2025
pulisher
May 14, 2025

EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors

May 14, 2025
pulisher
May 14, 2025

PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com

May 14, 2025
pulisher
May 14, 2025

Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025

Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Pds Biotechnology Corporation Azioni (PDSB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Glover Stephen C.
Director
Feb 28 '25
Buy
1.66
15,061
25,001
78,851
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Capitalizzazione:     |  Volume (24 ore):